HPN and prostate carcinoma: Since hepsin is specifically and significantly upregulated in prostate cancer tissues and metastatic cancer, it was anticipated to be a biomarker suitable for prostate cancer screening, diagnosis, or monitoring tumor progression using liquid biopsies.